Skip to main content
The Egyptian Journal of Internal Medicine
Fig. 2 | The Egyptian Journal of Internal Medicine

Fig. 2

From: Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

Fig. 2

Comparable percentages of patients who achieved SVR12 in Gp1 and Gp2. SVR12, sustained virological response; Gp, treatment group. Gp1 received sofosbuvir 400 mg/day plus daclatasvir 60 mg/day plus simeprevir 150 mg/day plus ribavirin 15 mg/kg/day for 12 weeks. Gp2 received sofosbuvir 400 mg/day plus ombitasvir 25 mg, paritaprevir 150 mg and ritonavir 100 mg/day plus ribavirin 15 mg/kg/day for 12 weeks

Back to article page